KRAS and Miyoshi myopathy: It is likely that KRAS-mutated cells survived the selection pressure imposed by combined anti-myeloma therapy (at the level of residual disease) but, with the evolution of MM, were dominated by other more aggressive clones at the time of overt relapse.